12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Other News

Covidien neurology news

Covidien plans to spin off its pharmaceuticals business into a separate public company that Covidien says will compete more effectively in the pain management area. The business accounted for $2 billion, or 17%, of Covidien's $11.6 billion net sales in FY11 ending Sept. 30, with 66% of pharma sales coming from the U.S....

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >